NCT00503568View on ClinicalTrials.gov

Vaccine Therapy in Treating Patients With Stage III, Stage IV, or Relapsed Non-Small Cell Lung Cancer Treated With First-Line Chemotherapy

PHASE1CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

May 31, 2007

Primary Completion Date

August 31, 2012

Study Completion Date

August 31, 2012

Conditions
Lung Cancer
Interventions
BIOLOGICAL

Ad100-gp96Ig-HLA A1

Dose Schedule 1 (DS-1): 4x10\^7 cells bi-weekly, maximum 9 vaccines/patient; Dose Schedule 2 (DS-2): 2X10\^7 cells weekly, maximum 18 vaccines/patient; Dose Schedule 3 (DS-3): 1x10\^7 cells twice weekly, maximum 36 vaccines/patient

Trial Locations (1)

33136

University of Miami Sylvester Comprehensive Cancer Center, Miami

All Listed Sponsors
lead

University of Miami

OTHER

NCT00503568 - Vaccine Therapy in Treating Patients With Stage III, Stage IV, or Relapsed Non-Small Cell Lung Cancer Treated With First-Line Chemotherapy | Biotech Hunter | Biotech Hunter